Published online Aug 6, 2020. doi: 10.12998/wjcc.v8.i15.3230
Peer-review started: January 14, 2020
First decision: April 12, 2020
Revised: April 25, 2020
Accepted: June 29, 2020
Article in press: June 29, 2020
Published online: August 6, 2020
Processing time: 205 Days and 8.3 Hours
The National Comprehensive Cancer Network clinical practice guidelines do not recommend palliative surgery for metastatic colorectal adenocarcinoma (CRA) unless there is a risk of significant acute bleeding, obstruction, perforation, or another severe symptom.
Accumulating evidence has demonstrated that palliative surgery for metastatic CRA patients was associated with more favorable outcomes. However, no studies further classified CRA patients with stage IV into subsets to assess the role of palliative surgery.
The purpose of this study was to investigate the separate role of palliative primary tumor resection for CRA patients with stage IVA (M1a diseases) and stage IVB (M1b diseases).
CRA patient records with definite M1a and M1b categories were analyzed by adjusted propensity score matching. Patient prognosis was assessed by univariate and multivariate Cox regression analyses with hazard ratios and 95% confidence intervals.
Patients with metastatic CRA receiving palliative primary tumor resection had a longer survival time than those who did not (P < 0.001). Palliative resection increased the median survival time by 9 mo and by 7 mo for patients with M1a and M1b diseases, respectively. For M1a diseases, patients with lung metastasis had more survival benefit from palliative resection than those with liver metastasis (15 mo for lung metastasis vs 8 mo for liver metastasis, P < 0.001).
Palliative primary tumor resection improves survival for all CRA patients but more beneficial for those with M1a diseases than those with M1b diseases. Specifically, patients with M1a (lung metastasis) had the best long-term outcomes after palliative primary tumor resection.
These findings provided further evidence to support the use of palliative surgical procedures to treat metastatic CRA and develop effective individualized treatment strategies.